Sim&Cure
Gonzague Issenmann has a diverse work experience spanning over several companies and industries. Gonzague currently serves as the Executive Chairman and CEO of Womed since February 2018. Additionally, they are a Board Director at AcuSurgical, Sim&Cure, and Sensome (formerly Instent) since joining these companies in 2021, 2019, and 2016 respectively.
Prior to these roles, Gonzague worked at Sofinnova Partners as an Entrepreneur In Residence from December 2016 to September 2019. Gonzague played a pivotal role in the success of STENTYS, a company they co-founded and led as the CEO from September 2005 to August 2016. During their tenure, they pioneered Self-Apposing(R) stent technology for coronary disease, secured significant funding, completed the product development cycle, and established commercialization in Europe and the Middle East.
Before joining STENTYS, Gonzague gained valuable experience at Johnson & Johnson in sales, marketing, and finance roles from January 2002 to August 2005. Gonzague also worked as a Project and Production Manager at Faurecia from April 1997 to December 2000, and as a Shift Supervisor at Saint Gobain from December 1995 to March 1997.
Overall, Gonzague Issenmann has a strong track record of leadership and entrepreneurial success in the medical technology industry, along with valuable experience in sales, marketing, finance, and project management.
Gonzague Issenmann obtained a Master of Science (MS) in Robotics from CentraleSupélec, where they studied from 1989 to 1995. Gonzague then pursued further education at INSEAD, completing an MBA in 2001.
This person is not in any teams
Sim&Cure
Sim&Cure is the first company to be cleared to market a patient-based simulation model for aneurysm treatment that allows prediction of the deployment of medical devices (flow diverter, intrasaccular device, laser-cuter stent). Sim&Size® simulates each size and type of device according to the patient’s unique anatomy in order to provideessential information prior to the choice of sizing.